SEC Comment Letter for Grace Therapeutics, Inc. (GRCE) (CIK 0001444192) (GRCE) — Aug 9, 2019
Grace Therapeutics, Inc. (GRCE) (CIK 0001444192)
Date: Aug. 9, 2019 · CIK: 0001444192 · Accession: 0000000000-19-012252
AI Filing Summary & Sentiment
File numbers found in text: 333-233063
Letter
August 8, 2019 Janelle D'Alvise Chief Executive Officer Acasti Pharma Inc. 545 Promenade du Centropolis, Suite 100 Laval, Québec, Canada H7T 0A3 Re:Acasti Pharma Inc. Registration Statement on Form F-3 Filed August 7, 2019 File No. 333-233063 Dear Ms. D'Alvise: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Jason Comerford, Esq.
Show Raw Text
August 8, 2019
Janelle D'Alvise
Chief Executive Officer
Acasti Pharma Inc.
545 Promenade du Centropolis, Suite 100
Laval, Québec, Canada H7T 0A3
Re:Acasti Pharma Inc.
Registration Statement on Form F-3
Filed August 7, 2019
File No. 333-233063
Dear Ms. D'Alvise:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Jason Comerford, Esq.